This is a working overview of certificate of analysis, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-23. Anything still debated is marked as such rather than presented as settled.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms and metabolic gene expression. In laboratory experiments, SR9009 binds these receptors and alters transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. It is not a naturally occurring compound and has no approved therapeutic use. Research interest stems from its ability to modify energy metabolism in cells and animal models.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
== Medical uses == Brief reactive psychosis and hypochondriasis-senestopathic syndrome Vegetative dysfunction and vegetative lability Alcohol withdrawal syndrome Temporal lobe epilepsy and myoclonic epilepsy (used only occasionally as better options exist) Hyperkinesia and tics Muscle spasticity Usually, a course of treatment with phenazepam should not normally exceed 2 weeks (in some cases therapy may be prolonged for up to 2 months) due to the risk of drug abuse and dependence. To prevent withdrawal syndrome, it is necessary to reduce the dose gradually.
=== Cytochrome P450 inhibitors and inducers === The cytochrome P450 enzymes involved in the metabolism of selegiline have not been fully elucidated. CYP2D6 and CYP2C19 metabolizer phenotypes did not significantly affect the pharmacokinetics of selegiline, suggesting that these enzymes are minimally involved in its metabolism and that inhibitors and inducers of these enzymes would not importantly affect its pharmacokinetics. However, although most pharmacokinetic variables were unaffected, overall exposure to selegiline's metabolite levomethamphetamine was 46% higher in CYP2D6 poor metabolizers compared to extensive metabolizers and exposure to its metabolite desmethylselegiline was 68% higher in CYP2C19 poor metabolizers compared to extensive metabolizers. As with the cases of CYP2D6 and CYP2C19, the strong CYP3A4 and CYP3A5 inhibitor itraconazole has minimal impact on the pharmacokinetics of selegiline, suggesting lack of major involvement of this enzyme as well. On the other hand, the anticonvulsant carbamazepine, which is known to act as a strong inducer of CYP3A enzymes, has paradoxically been found to increase exposure to selegiline and its metabolites levomethamphetamine and levoamphetamine by approximately 2-fold (with selegiline used as the transdermal patch form). One enzyme thought to be majorly involved in the metabolism of selegiline based on in-vitro studies is CYP2B6. However, there are no clinical studies of different CYP2B6 metabolizer phenotypes or of CYP2B6 inhibitors or inducers on the pharmacokinetics of selegiline.
== Science and technology == MSI Barcode, a continuous numeric barcode symbology Microsatellite instability, an abnormality of DNA Mass spectrometry imaging, a technique used in mass spectrometry Mass sociogenic illness, the rapid spread of physical symptoms of illness among the members of a group with no physical or infectious cause Magnetic source imaging, magnetoencephalography combined with magnetic resonance imaging Multispectral imaging, the capture of multiple, specific wavelengths in the electromagnetic spectrum Musculoskeletal injury, damage of muscular or skeletal systems which is usually due to a strenuous activity
== Signs and symptoms == The lesion is usually painless. The usual appearance is of two excess tissue folds in alveolar vestibule/buccal sulcus, with the flange of the denture fitting in between the two folds. It may occur in either the maxillary or mandibular sulci, although the latter is more usual. Anterior locations are more common than posterior. Less commonly there may be a single fold, and the lesion may appear on the lingual surface of the mandibular alveolar ridge. The swelling is firm and fibrous, with a smooth, pink surface. The surface may also show ulceration or erythema. The size of the lesion varies from less than 1 cm to involving the entire length of the sulcus.
Sources: en.wikipedia.org
Despite the fact that consistories in Freemasonry are only meant to administer the higher degrees, the Consistory believed it had authority to manage the Blue Lodges. The Supreme Council, despite being designed to administer the 33rd degree, had started chartering new Lodges without consulting the Grand Lodge of Colon. On May 22, 1860, Restauracion Lodge No. 4 was chartered in Jiguaní. In 1861, Amor Fraternal No. 5, Segunda Prudencia No. 6, and Dicipulos de Salomon No. 7 were chartered. In 1862, Fe Masonica Lodge was formed in Havana by members of Amor Fraternal.
=== Operation Theater Complex === The Operation Theater Complex was completed with PKR 260 million and was finally inaugurated on the Saturday 27 April 2019 having four State-of-the-art Operation theaters with a total capacity of 60 beds of which 10 are in the surgical ICU.
The N-hydroxyphthalimide can be removed by shaking with sodium bicarbonate, but the N-hydroxysuccinimide approach shows greater reactivity and convenience, and is generally preferred. Esters of N-hydroxyphthalimide and activated sulfonic acids such as trifluoromethanesulfonic anhydride or p-toluenesulfonyl chloride are used as so-called photoacids, which split off protons during UV irradiation.
Sources: en.wikipedia.org
Latinopoulou has long accused New Democracy under Mitsotakis of being a center-left party masquerading as a center-right party and Mitsotakis as an "unrepentant socialist" and secret leftist, and that after over half a decade in government that the current state of homelessness, unsafe trains, and drug dealing and criminality in the public universities is something that after so many years in power New Democracy must support, since, according to Latinopoulou "What they tolerate they want") While refusing to vote for an EU inquiry into the Tempi case due to what she has argued would create a dangerous EU legal authority precedence in Greece, she has nonetheless called what she views as the Mitsotakis' government having done "nothing" to make the trains safer since the incident as a sign of their "heartlessness" and supports Greek legal inquiries but not EU legal inquiries into the matter. She has publicly stated as well that on the character of Kyriakos Velopoulos and as well on the case of Tempi that he is a "know-it-all geezer" who is a "fraud and a scammer" and that she is the only serious right-wing alternative to the "center left New Democracy party."
== Mechanotaxis in wound healing == In wound healing, fluid shear stress plays a large role in the mechanotaxis of endothelial cells to the wound site. The inner lining of blood vessels is composed of these endothelial cells, which means that these cells are continuously experiencing fluid shear stress from blood rushing through the vessels. This mechanical stress on the apical side of the endothelial cells leads to integrin signaling, which involves the recruitment of focal adhesion kinase (FAK), Shc, and Crk, and will lead to changes in cell-cell and cell-ECM adhesion. These changes involve lamellipodial protrusions and focal adhesion (FA) formation at the front of the cell, as well as the dismantling of FAs at the rear of the cell, and cause endothelial cells to move in the direction of the flow. Constant laminar flow has been found to improve cell migration in wounds and increases the rate of wound closure.
Tim Hortons reportedly had plans by 2013 to enter the large Indian market, which the company denied. In an effort to expand the company following its 2014 merger with Burger King into Restaurant Brands International, Tim Hortons began expansion in Asia in 2017 citing the increasing demand for coffee in large populations. The first Southeast Asian branch was opened in the Philippines on February 28, 2017, at Uptown Mall in Bonifacio Global City, Taguig. Siera Bearchell, Miss Universe Canada 2016, was present for the ribbon-cutting ceremony. As of December 2023, there are 52 locations operating in the Philippines.
==== July 2025 rescissions ("claw backs"), but not for PEPFAR ==== In June 2025, the White House requested that Congress pass a package of rescissions, or "claw backs", of approximately $8 billion in foreign aid and $1 billion for the Corporation for Public Broadcasting including NPR and PBS. The House of Representatives passed the cuts as requested. The Senate excluded the PEPFAR cuts, which is the program started in 2003 during the presidency of George W Bush to help provide HIV medicines to lower-income countries. The Senate passed two preliminary votes in close 51-50 fashion with Vice President JD Vance casting the tie-breaking votes. A rescission is one of the exceptions to the Senate's 60-vote filibuster rule. President Trump focused on the public broadcasting aspect, criticizing CNN and also "MSDNC" which is a mix of MSNBC and DNC (Democratic National Committee). In a Truth Social post, he wrote, "It is very important that all Republicans adhere to my Recissions Bill and, in particular, DEFUND THE CORPORATION FOR PUBLIC BROADCASTING (PBS and NPR), which is worse than CNN & MSDNC put together." In a late night session at 2:00 AM on July 17, the Senate voted 51–48 in favor of the cuts. Later that same day, the House of Representatives voted 216 - 213 for the Senate version, meaning PEPFAR was protected in the amount of $400 million. Regarding the cuts to public broadcasting, service to rural areas became one of the political issues.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.